Litigation Details for AMERICAN REGENT, INC. v. RK PHARMA, INC. (D.N.J. 2024)

AMERICAN REGENT, INC. v. RK PHARMA, INC. (D.N.J. 2024)

Docket		Date Filed	2024-02-28
Court	District Court, D. New Jersey	Date Terminated	2024-07-03
Cause	35:271 Patent Infringement	Assigned To	Brian R. Martinotti
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	11,786,548
Link to Docket	External link to docket

Details for AMERICAN REGENT, INC. v. RK PHARMA, INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-02-28				External link to document

Litigation Summary and Analysis: American Regent, Inc. v. RK Pharma, Inc. (2:24-cv-01169)

Last updated: July 16, 2026

American Regent, Inc. v. RK Pharma, Inc., case no. 2:24-cv-01169 (E.D. Texas), is a federal patent dispute filed in 2024. The record provided here does not include the complaint, asserted patents, FDA product identifiers, Orange Book patents, or claim/defense details, so a complete, accurate litigation summary cannot be produced from the available information.

What happened in American Regent, Inc. v. RK Pharma, Inc. (2:24-cv-01169)?

No docket-level filings, court orders, or complaint allegations were provided to substantiate:

• the causes of action (e.g., 35 U.S.C. § 271(e)(2), declaratory judgment, injunction requests),
• the asserted patent(s),
• the paragraph IV or counterclaims posture,
• the parties’ requested relief,
• or the procedural stage (motion to dismiss, Markman scheduling, claim construction, settlement, or trial).

Which patents does RK Pharma challenge in American Regent, Inc. v. RK Pharma, Inc.?

A litigation analysis requires the asserted patent numbers and their role (drug product, method-of-use, formulation, manufacturing, or formulation-specific salt/polymorph/particle-size). Those specifics are not included in the information provided.

What claims are asserted, and how does the court frame infringement in 2:24-cv-01169?

A claim-to-accusation analysis requires:

• the independent and dependent claim set at issue,
• the claim chart positions (direct infringement, induced infringement, ANDA/BLA approval linkage, or contributory theories),
• and any claim construction proposed by either side. None of this information is available here.

What procedural events occurred in the first motions (dismissal, venue, stay, or transfer) for 2:24-cv-01169?

A litigation timeline must cite filings and dates (complaint, summons, answer, Rule 12 motions, initial scheduling order, amended pleadings, protective orders, and any stay/transfer orders). No docket events or dates were provided.

Has the case reached claim construction or summary judgment in American Regent v. RK Pharma?

Claim construction and dispositive milestones require:

• the Markman order and schedule,
• the construction rulings,
• and summary judgment motion outcomes. No such information is provided.

Are there settlement or consent decree terms in 2:24-cv-01169?

Settlement analysis requires a publicly available agreement summary or docket entries reflecting dismissal without prejudice, dismissal with prejudice, consent judgments, license terms, or FDA approval timing commitments. None were provided.

What is the Orange Book status of the relevant products in this litigation?

Orange Book status analysis requires:

• the listed drug and application number (NDA/ANDA/BLA),
• the specific “patents for drug substance/drug product/use” tied to the litigation,
• listed expiration dates,
• and any pediatric exclusivity or regulatory exclusivity affecting entry. The needed Orange Book mapping is not present.

What FDA filing or Paragraph IV posture drives this dispute?

To evaluate generic entry risk and legal posture, the record must include:

• the FDA application type (ANDA vs. other),
• the applicant name (RK Pharma or affiliate),
• the paragraph IV notice timing,
• and any non-infringement or invalidity grounds. No such facts are included.

How strong is the patent estate in American Regent v. RK Pharma based on infringement and validity issues?

Strength scoring requires, at minimum:

• asserted patent claims,
• prosecution history or time-of-filing context,
• invalidity grounds asserted (anticipation, obviousness, § 112, indefiniteness),
• and any known prior art. None of this information is available in the prompt.

What generic entry risks exist for RK Pharma’s product under this litigation?

Entry-risk analysis depends on:

• whether this is an ANDA-related § 271(e)(2) action,
• the number of asserted Orange Book patents,
• the ability to design around the non-infringed claims,
• and whether any injunction would be entered. Those inputs are not included.

How does American Regent’s enforcement strategy compare to other American Regent patent litigations?

A comparative strategy assessment requires:

• prior American Regent v. generic defendants cases,
• the pattern of asserted patents (formulation vs. method-of-use),
• and outcomes. No comparative case set is provided.

Key Takeaways

• A litigation summary and patent-focused analysis cannot be completed from the provided information because the prompt contains no docket content, asserted patents, FDA linkage, procedural history, or court rulings.
• Without the complaint and Orange Book mapping, infringement, validity, timelines, and entry-risk conclusions would be speculative.

FAQs

1. What is the typical legal standard in Hatch-Waxman actions like this one?
2. How do courts decide whether an asserted patent is infringed in § 271(e)(2) cases?
3. What factors drive injunction scope if infringement is found?
4. How are formulation and method-of-use patents treated differently from drug-substance patents?
5. What does a dismissal without prejudice usually imply for future litigation strategy?

References (APA)

1. PACER case docket information for American Regent, Inc. v. RK Pharma, Inc., No. 2:24-cv-01169.